May 26, 2020
1 min read
Save
Multi-antigen T-Cell Infusion Against Neuro-oncologic Disease
Issue: May 2020
Phase 1 dose-escalation trial to determine the safety and feasibility of rapidly generated tumor multi-antigen associated specific cytotoxic T lymphocytes in patients with newly diagnosed diffuse intrinsic pontine gliomas or recurrent, progressive or refractory nonbrainstem CNS malignancies.
